AstraZeneca chief quits CSL board over $50 billion acquisition

  • 📰 theage
  • ⏱ Reading Time:
  • 18 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 77%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

AstraZenaca’s Pascal Soriot will depart the CSL board next month to prevent potential conflicts of interest after his company bought a US immunology startup.

AstraZeneca chief executive Pascal Soriot will leave CSL’s board just months after being appointed over fears of a potential future conflict of interest between the two biotechnology giants.

Based in Boston, Alexion develops treatments for rare diseases including in the blood and heart conditions, where CSL is a major player. Mr Soriot was not set to be directly involved in discussions about the AstraZeneca vaccine production and it was planned he would abstain from board issues where there was a potential conflict of interest.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 8. in İD
 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.

Too late insider trading information already used

Indonesia Berita Terbaru, Indonesia Berita utama